Max Healthcare Revenue Up 10%, But Margins Squeeze Amid Expansion Costs

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Max Healthcare Revenue Up 10%, But Margins Squeeze Amid Expansion Costs
Overview

Max Healthcare Institute Limited posted a 10% year-on-year increase in Q3 FY26 gross revenue, reaching ₹2,608 crore, driven by higher occupied bed days. However, operating EBITDA grew by a slower 4% to ₹648 crore, and EBITDA margins compressed by 1.2 percentage points to 26.1%. Profit after tax rose 9% YoY to ₹344 crore. The company is actively pursuing significant capacity expansion across multiple locations, including a new hospital in Pune by 2030.

Financial Deep Dive

Max Healthcare Institute Limited has reported its financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26), showcasing a robust 10% year-on-year increase in gross revenue to ₹2,608 crore. This top-line growth was primarily fueled by a 7% rise in occupied bed days. However, the company's operating EBITDA saw a more modest 4% year-on-year increase, reaching ₹648 crore. Crucially, operating EBITDA margins contracted by 1.2 percentage points to 26.1% compared to Q3 FY25.

Profit after tax (PAT) for the quarter stood at ₹344 crore, reflecting a 9% year-on-year growth. This figure was after accounting for exceptional items totaling ₹55 crore, related to the impact of the Code on Wages and stamp duty on subsidiary mergers.

Sequentially, the performance saw a dip, with revenue declining by 3.1% and EBITDA by 10.5% from the previous quarter (Q2 FY26). This was attributed to temporary disruptions in health insurer services and the discontinuation of certain low-margin chemotherapy drugs impacting institutional patient volumes.

The Numbers:

  • Gross Revenue: ₹2,608 crore (Up 10% YoY)
  • Operating EBITDA: ₹648 crore (Up 4% YoY)
  • EBITDA Margin: 26.1% (Down 1.2 pp YoY)
  • Profit After Tax (PAT): ₹344 crore (Up 9% YoY)
  • Exceptional Items: ₹55 crore
  • Free Cash Flow: ₹281 crore
  • Net Debt: ₹2,166 crore (Net Debt to EBITDA ratio below 1)

The Quality:

The revenue growth was underpinned by increased patient volumes (occupied bed days). Average Revenue Per Occupied Bed (ARPOB) saw a marginal 3% year-on-year increase to ₹77,900. The compression in EBITDA margins was influenced by a change in the payor mix, pre-commissioning expenses for new brownfield beds, and changes in GST rates.

Risks & Outlook

Management expressed confidence in future growth, anticipating benefits from the restoration of cashless services with insurers and expected CGHS tariff revisions from April 2026. The commissioning of new, margin-accretive capacities is also a key growth driver.

Specific Risks:

  • Margin pressure due to payor mix shifts and regulatory tariff revisions.
  • Pre-commissioning expenses associated with new bed capacities.
  • Impact of GST rate changes and drug pricing policies.
  • Potential short-term disruption from health insurer service fluctuations.

Negative History:

Searches for significant fraud, SEBI penalties, or major governance issues directly impacting Max Healthcare's current operational integrity did not yield adverse findings. However, a past controversy involved allegations of a conflict of interest concerning SEBI Chairperson Madhabi Puri Buch's prior directorship at Max Healthcare Institute Ltd. This arose in relation to transactions involving Axis Bank and Max Life Insurance. The Delhi High Court noted that while these allegations were raised, they did not prevent SEBI from continuing its regulatory duties, emphasizing that any final decision could be challenged if it were found to be influenced by past associations.

The Forward View:

Investors will be keenly watching the successful ramp-up of new hospital capacities and the company's ability to navigate margin pressures. The upcoming commissioning of new facilities and positive regulatory catalysts are expected to support future growth. The company's expansion strategy includes a substantial ~450-bed hospital in Pune, targeted for commissioning by 2030.

Peer Comparison

Apollo Hospitals reported a robust Q3 FY26 with a 17% YoY revenue increase to ₹6,477 crore and a 35% YoY net profit jump to ₹502 crore. Its EBITDA rose 27% to ₹965 crore, with EBITDA margins reported at 14.9%, showcasing strong operational performance driven by its healthcare services and expansion plans.

Fortis Healthcare also posted strong results, with its September quarter (Q3 FY26) seeing an 86% YoY surge in net profit to ₹328 crore and revenue growth to ₹2,331 crore. Its hospital business demonstrated healthy revenue growth and improved operating margins.

Narayana Hrudayalaya reported Q3 FY26 revenue of ₹1,643.79 crore, a 9.06% QoQ increase. However, its operating profit saw a slight QoQ decrease, though Net Profit grew significantly YoY and QoQ.

While Max Healthcare is expanding its footprint, its margin performance in Q3 FY26 shows greater pressure compared to some peers, highlighting the cost implications of its strategic growth initiatives.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.